Says Austedo IRA price negotiations in-line with forecast. Says fundamentals of Austedo “very strong.” Expects to build momentum with biosimilars in Europe.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva says terminated exclusive discussions with select buyer for TAPI
- Teva says ‘clear path’ to 30% operating margin by 2027
- Teva says not moving forward with discussions for sale of TAPI
- Teva says net debt/EBITDA below 3.0x for first time since 2016
- Teva sees Austedo sales greater than $2.5B in 2027